Buchumschlag

RETRACTION: Interleukin‐4 Activates Androgen Receptor Through CBP/p300

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	The Prostate
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

RETRACTION: Lin28 Induces Resistance to Anti‐Androgens via Promotion of AR Splice Variant Generation
Veröffentlicht: (2026)

Transcriptomic Signatures of Monocyte‐Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer
von: Marina Nasrin Sharifi, et al.
Veröffentlicht: (2025)

Therapeutic Exhaustion After Upfront Androgen Receptor Signaling Inhibitor: A Hidden Determinant of Post‐CRPC Survival
von: Shengyi Chen, et al.
Veröffentlicht: (2026)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
von: Mitsuhisa Nishimoto, et al.
Veröffentlicht: (2025)

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
von: Kazuma Yukihiro, et al.
Veröffentlicht: (2026)

pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post‐Initiation of Androgen Deprivation Therapy
von: Piotr Bialas, et al.
Veröffentlicht: (2024)

Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
von: Kazuro Kikkawa, et al.
Veröffentlicht: (2024)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
von: Himawari Asanuma, et al.
Veröffentlicht: (2026)

Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in Prostate Cancer
von: Yu‐Hsiang Lin, et al.
Veröffentlicht: (2025)

Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting
von: Tanya Stoyanova, et al.
Veröffentlicht: (2025)

Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
von: Masanori Ishida, et al.
Veröffentlicht: (2025)

Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High‐Risk Prostate Cancer
von: Hanyang Tao, et al.
Veröffentlicht: (2024)

Long‐Term Follow‐Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial
von: Braden Millan, et al.
Veröffentlicht: (2025)

Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
von: Cem Onal, et al.
Veröffentlicht: (2026)

Autocrine Fibroblast Growth Factor Receptor 1 Signaling Activates Lactate Dehydrogenase A‐Aerobic Glycolysis for Advanced Human Prostate Tumor Growth
von: Xiaoming Xu, et al.
Veröffentlicht: (2025)

Significant Effect of Carbon‐Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High‐Risk Prostate Cancer Patients: A Two‐Center Controlled Trial Compare With X‐Ray External Beam Radiation Therapy
von: Xue Zhao, et al.
Veröffentlicht: (2024)

Valosin‐Containing Protein (VCP/p97) Mediates Neuroendocrine Differentiation in Prostate Cancer Cells Through Pim1 Signaling Inducing Autophagy
von: K. K. Sruthi, et al.
Veröffentlicht: (2025)

Human Epidermal Growth Factor Receptor 2 Expression in Prostatic Carcinomas: A Systematic Review and Meta‐Analysis of a Potential Therapeutic Target
von: Jacky T. F. Luk, et al.
Veröffentlicht: (2026)

RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα
Veröffentlicht: (2024)

Optimizing Prostate Cancer Diagnostic Work‐Up Through Micro‐Ultrasound: Minimizing Unnecessary Procedures and Reducing Overdiagnoses
von: Edoardo Beatrici, et al.
Veröffentlicht: (2025)

EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells
Veröffentlicht: (2026)

LIAS Promotes Cuproptosis in Prostate Cancer Cells by Suppressing Glycolysis via the p53 Signaling Pathway
von: Zhe Tang, et al.
Veröffentlicht: (2025)

Cover Image: Volume 86 Issue 4
von: Shannon Carskadon, et al.
Veröffentlicht: (2026)

A Gene Expression Tumor Signature Optimizing Partial Area‐Under‐the‐Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer
von: Travis A. Gerke, et al.
Veröffentlicht: (2026)

Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study
von: Ezra G. Baraban, et al.
Veröffentlicht: (2025)

Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy
von: Victor Sandoval, et al.
Veröffentlicht: (2025)

Dorsomorphin Suppresses EMT to Reduce AR‐Negative Prostate Cancer Metastasis by Synergistically Antagonizing JAK2/STAT3 and Gli2‐Independent Shh Activation
von: Dongzhang Li, et al.
Veröffentlicht: (2025)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
von: Takanori Tokunaga, et al.
Veröffentlicht: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
von: Yuto Ono, et al.
Veröffentlicht: (2025)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
von: Hyun‐Kyung Ko, et al.
Veröffentlicht: (2025)

Discovering the Prostate: Notes on History and Historiography
von: Diederik F. Janssen
Veröffentlicht: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
von: Fabian Falkenbach, et al.
Veröffentlicht: (2025)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
von: Mark Kidd, et al.
Veröffentlicht: (2025)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
von: Meryam Losee, et al.
Veröffentlicht: (2025)

Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study
von: Zhiyao Xu, et al.
Veröffentlicht: (2025)

Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region
von: Angel Borque‐Fernando, et al.
Veröffentlicht: (2025)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
von: Christian P. Pavlovich, et al.
Veröffentlicht: (2025)

Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro
von: Megan H. Check, et al.
Veröffentlicht: (2025)

Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort
von: Victor Yu, et al.
Veröffentlicht: (2025)

The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer
von: Trevor C. Hunt, et al.
Veröffentlicht: (2025)